Prior information notice
This notice aims at reducing time limits for receipt of tenders
Section I: Contracting
authority
I.1) Name and addresses
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
UK
Contact person: Surinder Kahlon
E-mail: surinder.kahlon@nhs.net
NUTS: UKJ1
Internet address(es)
Main address: https://www.england.nhs.uk/
Address of the buyer profile: https://www.england.nhs.uk/
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://atamis-1928.my.site.com/s/Welcome
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://atamis-1928.my.site.com/s/Welcome
Tenders or requests to participate must be sent to the abovementioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
https://atamis-1928.my.site.com/s/Welcome
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Market Engagement for Onasemnogene Abeparvovec (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service
Reference number: C410884
II.1.2) Main CPV code
85100000
II.1.3) Type of contract
Services
II.1.4) Short description
The key objective of the Market Engagement Exercise is to seek feedback from the market regarding levels of interest, capability and capacity in relation to delivering the onasemnogene abeparvovec (zolgensma®) service and the onasemnogene abeparvovec intrathecal (OAV101 IT) service
II.1.5) Estimated total value
Value excluding VAT:
.01
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.3) Place of performance
NUTS code:
UK
II.2.4) Description of the procurement
The key objective of the Market Engagement Exercise is to seek feedback from the market regarding levels of interest, capability and capacity in relation to delivering the onasemnogene abeparvovec (zolgensma®) service and the onasemnogene abeparvovec intrathecal (OAV101 IT) service.<br/><br/>The commissioner isinterested in receiving feedback from the market on their capability and capacity to deliver services for zolgensma® or combined (zolgensma® and OAV101 IT).<br/><br/>It is also anticipated that the findings from this market engagement exercise will assist in the decision-making for the approach to commissioning the Service(s).<br/><br/>If, as a result of the market engagement, competition is absent or minimal, in any of the potential Lots/Regions, the Commissioner may use the Most Suitable Provider Process or Direct Award Process C. Where competition is absent, Direct Award Process A may be utilised. If, as a result of the market engagement, competition is apparent in a potential Lot/Region , a Competitive Process may be undertaken to award the contract for that Lot.<br/><br/>Service Summary:<br/>Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. The severity of SMA can vary greatly between individuals. Historically, the condition has been classified into different types, determined by clinicians at the time of diagnosis. This classification is based on both the age at which symptoms first appear, and the highest level of motor function achieved by the patient. <br/><br/>The types range from type 0, the most severe form, where symptoms are present before birth and most affected infants don’t survive past 6 months, through to type 4, which develops in adulthood and is associated with mild motor impairment and a normal life span. However, because the disease presents so variably, consistently categorising patients into these types at the point of diagnosis can be challenging.<br/>Onasemnogene abeparvovec (zolgensma®) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time gene therapy for patients with SMA, proposed to treat people with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct population from the indication for Zolgensma®. <br/><br/>Following market engagement and review of capable providers, the Commissioner will consider the most appropriate PSR process(es) to formally commission each service. Interested parties may respond to this Market Engagement Exercise in partnership with other organisations as part of a consortium, subject to them appointing a consortium lead to act on their behalf as the lead contracting party would take overall responsibility for delivery of the service(s) in accordance with the requirements of any future contract(s) if successful.<br/><br/>To express interest and participate in the Market Engagement Exercise, please register and apply via Atamis esourcing portal https://health-family.force.com/s/Welcome <br/>Should Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:<br/>Phone: 08000988201<br/>E-mail: support-health@atamis.co.uk<br/>The closing date for completed Market Engagement responses is 12:00pm (noon), on Monday 2nd February 2026.<br/>Atamis Project reference C410884.
II.2.5) Award criteria
Criteria below:
Price
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 108
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
II.3) Estimated date of publication of contract notice:
12/03/2026
Section IV: Procedure
IV.1) Description
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section VI: Complementary information
VI.4) Procedures for review
VI.4.1) Review body
NHS Arden and Greater East Midlands Commissioning Support Unit
Cardinal Square, 10 Nottingham Road
Derby
DE1 3QT
UK
Internet address(es)
URL: https://www.ardengemcsu.nhs.uk/
VI.5) Date of dispatch of this notice
08/01/2026